D.A. Davidson & CO. Purchases 4,673 Shares of Organon & Co. (NYSE:OGN)

D.A. Davidson & CO. raised its position in Organon & Co. (NYSE:OGN) by 3.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 126,820 shares of the company’s stock after buying an additional 4,673 shares during the period. D.A. Davidson & CO.’s holdings in Organon & Co. were worth $1,892,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of OGN. Pacer Advisors Inc. boosted its position in shares of Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Weiss Asset Management LP bought a new position in shares of Organon & Co. in the 3rd quarter worth $32,966,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Organon & Co. by 303.8% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after purchasing an additional 934,505 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Organon & Co. by 35.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock worth $63,570,000 after purchasing an additional 875,128 shares during the last quarter. Finally, Philip James Wealth Mangement LLC acquired a new stake in Organon & Co. during the 3rd quarter worth $15,386,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Trading Down 1.4 %

Shares of NYSE:OGN opened at $15.47 on Friday. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The stock has a market cap of $3.98 billion, a PE ratio of 4.64, a P/E/G ratio of 0.90 and a beta of 0.76. The business has a 50 day moving average of $15.36 and a 200-day moving average of $17.27. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. As a group, equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be given a $0.28 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.24%. Organon & Co.’s payout ratio is 33.63%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. Barclays reduced their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.